DYN Earnings & Financial Statements
Dyne Therapeutics, Inc.
$15.35
+$0.31(+2.06%)
37
Overall
50
Value
27
Tech
34
Quality
Market Cap
$2.81B
Volume
493.12K
52W Range
$13.73 - $27.31
Target Price
$36.00
DYN earnings and financial statements: Dyne Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
DYN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$468.18M | -$343.89M | -$242.16M | -$170.96M | -$150.03M |
| EBITDA | -$438.02M | -$315.72M | -$234.24M | -$165.12M | -$148.94M |
| Net income | -$446.21M | -$317.42M | -$235.94M | -$168.10M | -$149.29M |
| EPS (diluted) | $-3.47 | $-3.37 | $-3.95 | $-3.23 | $-2.93 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.19B | $691.23M | $165.08M | $306.32M | $425.66M |
| Total liabilities | $214.83M | $61.40M | $73.79M | $53.96M | $57.47M |
| Shareholders’ equity | $972.13M | $629.84M | $91.29M | $252.36M | $368.20M |
| Cash and equivalents | $893.37M | $435.45M | $121.63M | $172.15M | $200.82M |
| Long-term debt | $164.20M | $19.14M | $22.70M | $25.87M | $28.74M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$403.21M | -$292.37M | -$188.16M | -$153.65M | -$119.56M |
| Capital expenditure | -$20.71M | -$2.38M | -$729.0K | -$3.07M | -$3.62M |
| Free cash flow | -$423.92M | -$294.75M | -$188.89M | -$156.71M | -$123.18M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DYN | $15.35 | +2.1% | 493.12K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |